Drug Safety

, Volume 25, Issue 7, pp 473–483

‘Sleep Attacks’ or ‘Unintended Sleep Episodes’ Occur with Dopamine Agonists

Is This a Class Effect?
  • K. Ray Chaudhuri
  • Suvankar Pal
  • Christine Brefel-Courbon
Current Opinion

Abstract

Controversial reports of sudden onset ‘sleep attacks’ resulting in road traffic accidents have recently been reported in patients with Parkinson’s disease (PD) taking the non-ergot dopamine D2/D3 receptor agonists pramipexole and ropinirole. These reports have generated considerable debate as the concept of ‘sleep attacks’ is disputed amongst sleep specialists and most believe that isolated ‘sleep attacks’ not preceded by warning on the background of chronic sleepiness or ‘unintended sleepiness’ do not exist. A series of case reports suggested that this phenomenon may not be exclusive to the non-ergot dopamine agonists such as pramipexole or ropinirole and indeed may occur with most dopaminergic agents. Recent evidence suggest that a ‘sleepiness’ or ‘hypoactivity’ reaction to dopaminergic therapy may be related to underlying dopamine deficiency of PD rather than a drug effect. In this report we provide the evidence for the phenomenon being a class effect attributable to all dopamine agonists currently employed in the management of PD.

Controversy surrounding excessive daytime sleepiness (EDS) in PD and the use of the Epworth Sleepiness Scale (ESS) in relation to PD is also discussed. In spite of variable reports, EDS is recognised to be common in PD and is likely to be related to both the disease process and drug therapy. Studies using multiple sleep latency tests have also reported differing results in PD although a recent study indicated that a subset of ‘sleepy’ patients with PD may experience pathological somnolence with resultant detrimental consequence on daytime and cognitive functions. We recommend that the issue of ‘sleepiness’ or ‘sleep attacks’ in PD should be routinely checked in all patients with PD and indirectly assessed by using either the ESS or the recently introduced Parkinson’s Disease Sleep Scale. Those with reported ‘sleep attacks’ or ‘unintended sleep episodes’ and excessive daytime sleepiness while taking dopamine agonists or dopaminergic agents such as levodopa should have a review of their medication, should not be driving a car on their own and some may merit formal sleep architecture studies. The latter may identify sleep disorders such as secondary narcolepsy which may benefit from the use of a wakefulness promoting agent.

References

  1. 1.
    Frucht S, Roger JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908–10PubMedCrossRefGoogle Scholar
  2. 2.
    Olanow CW, Schapira AH, Roth T. Waking up to sleep episodes in Parkinson’s disease Mov Disord 2000; 15: 212–5PubMedCrossRefGoogle Scholar
  3. 3.
    Hoehn MM. Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole [letter]. Neurology 2000; 54: 275PubMedGoogle Scholar
  4. 4.
    Schapira AH. Sleep attacks (sleep episodes) with pergolide. Lancet 2000; 355: 1332–3PubMedCrossRefGoogle Scholar
  5. 5.
    Ferreira JJ, Galitsky M, Montastruc JL, et al. Sleep attacks and Parkinson’s disease treatment. Lancet 2000; 355: 1333–4PubMedCrossRefGoogle Scholar
  6. 6.
    Jiminez-Jiminez FJ, Sayed Y, Garcia-Soldevilla MA, et al. ‘Sleep attacks’ induced by pergolide. Parkinsonism Related Disord 2001; 7: S59Google Scholar
  7. 7.
    Homann CN, Wenzel K, Suppan K, et al. Sleep attacks after acute administration of apomorphine [abstract]. Mov Disord 2000; 15Suppl. 3: P585Google Scholar
  8. 8.
    Olanow CW, Schapira AHV, Roth T. Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole [editorial]. Neurology 2000; 54: 274PubMedCrossRefGoogle Scholar
  9. 9.
    Chamraj SC, Schulzer M, Stoessl J, et al. Daytime sleepiness and antiparkinson treatment [abstract]. Neurology 2001; 56(3): A213Google Scholar
  10. 10.
    Stover NP, Okun MS, Watts RL. ‘Sleep attacks’ and excessive daytime sleepiness (EDS) in Parkinson disease: a survey of 200 consecutive patients [abstract]. Neurology 2001; 56(3): A213Google Scholar
  11. 11.
    Andreu N, Chale JJ, Senard JM, et al. L-dopa induced sedation: a double blind cross-over controlled study versus triazolam and placebo in healthy volunteer. Clin Neuropharmacol 1999; 22: 15–23PubMedCrossRefGoogle Scholar
  12. 12.
    American Sleep Disorders Association. International classification of sleep disorders revised: diagnostic and coding manual. Rochester (MN): American Sleep Disorders Association, 1997Google Scholar
  13. 13.
    Tan EK, Lum SY, Fook-Chong SMC, et al. Evaluation of somnolence in Parkinson’s disease: comparison with age and sex matched controls. Neurology 2002; 3: 465–8CrossRefGoogle Scholar
  14. 14.
    Rascol O, Ferreira JJ, Desboeuf K, et al. Sleep disruption, daytime somnolence, and ‘sleep attacks’ in Parkinson’s disease: a clinical survey in PD patients and age-matched healthy volunteers [abstract]. Neurology 2001; 56(3): A212Google Scholar
  15. 15.
    Arnulf I, Konofal E, Mereno-Andreu M, et al. Clinical profiles of somnolence in Parkinon’s disease. Neurology. In pressGoogle Scholar
  16. 16.
    Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology 2002; 58(3): 341–6PubMedCrossRefGoogle Scholar
  17. 17.
    Saletu MT, Glatzl S, Brandauer E, et al. Pergolide induced insomnia and daytime sleepiness in a patient with Parkinson’s disease resolved by switching to ropinirole [abstract]. Sleep 2001; 24: A370Google Scholar
  18. 18.
    Nakamishi T, Kowa H, Mizuno Y, et al. The clinical evaluation of B-HT 920 (talipxole hydrochloride) in Parkinson’s disease: a multicentred double-blind comparative study vs bromocriptine mesilate. Clin Eval 1993; 21: 50–110Google Scholar
  19. 19.
    Nishino S, Ripley B, Overeem S, et al. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39–40PubMedCrossRefGoogle Scholar
  20. 20.
    Ripley B, Overeem S, Fujuki N, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001; 57: 2253–8PubMedCrossRefGoogle Scholar
  21. 21.
    Nishino S, Arrigno J, Valtier D, et al. Dopamine D2 mechanisms in canine narcolepsy. J Neurosci 1999; 11: 2666–71Google Scholar
  22. 22.
    Reid M, Tafti M, Nishino S, et al. Local administration of dopaminergic drugs into the ventral tegmental area modulates cataplexy in the narcolpetic canine. Brain Res 1996; 733: 83–100PubMedCrossRefGoogle Scholar
  23. 23.
    Pinter MM, Pogarell O, Oertel WH. Efficacy, safety and tolerability of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66: 436–41PubMedCrossRefGoogle Scholar
  24. 24.
    Hauser RA, Gauger L, Anderson WM, et al. Pramipexole induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15: 658–63PubMedCrossRefGoogle Scholar
  25. 25.
    Rascol O, Brooks DJ, Korczyn AD, et al. A five year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinriole or levodopa. N Engl J Med 2000; 342: 1484–91PubMedCrossRefGoogle Scholar
  26. 26.
    Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson’s disease. JAMA 1997; 278: 125–130Google Scholar
  27. 27.
    Ferreira JJ, Galitzky M, Thalamas C, et al. Effect of ropinirole on sleep onset: a randomised, placebo controlled study in healthy volunteers. Neurology 2002; 58(3): 460–1PubMedCrossRefGoogle Scholar
  28. 28.
    Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson’s disease: a randomised controlled trial. JAMA 2000; 284: 1931–8Google Scholar
  29. 29.
    Montastruc JL, Brefel-Courbon C, Senard JM, et al. Sudden sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiological study. Clin Neuropharmacol 2001; 24: 181–3PubMedCrossRefGoogle Scholar
  30. 30.
    Ondo WG, Vuong KV, Khan H, et al. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology 2001; 57: 1392–6PubMedCrossRefGoogle Scholar
  31. 31.
    Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden onset sleep in Parkinson’s disease: a survey by the Canadian Movement Disorders group. JAMA 2002; 287(4): 455–63PubMedCrossRefGoogle Scholar
  32. 32.
    Carbonari E, DeNoteris R, De Gasperi D, et al. Daily somnolence and night sleep in Parkinson disease: role of treatment and disease severity [abstract]. Neurology 2001; 56(3): A213Google Scholar
  33. 33.
    Happe S, Berger K. The influence of dopamine agonists on daytime sleepiness, sleep disturbances, and quality of life in patients with Parkinson’s disease [abstract]. Sleep 2001; 24: A371Google Scholar
  34. 34.
    Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson’s disease: a community based study. Mov Disord 1999; 14: 922–7PubMedCrossRefGoogle Scholar
  35. 35.
    Factor SA, McAlarney T, Sanchez Ramos JR, et al. Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord 1999; 5: 280–5CrossRefGoogle Scholar
  36. 36.
    Pal S, Bhattacharya KF, Agapito C, et al. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson’s disease patients taking pramipexole, cabergoline, and levodopa mono and combination therapy. J Neural Transm 2001; 108: 71–7PubMedCrossRefGoogle Scholar
  37. 37.
    Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540–5PubMedGoogle Scholar
  38. 38.
    Sanjiv CC, Schulzer M, Mak E, et al. Daytime somnolence in patients with Parkinson’s disease. Parkinsonism Related Disord 2001; 7(S2001): 283–6CrossRefGoogle Scholar
  39. 39.
    Appiah-Kubi L, Forbes A, Gunawardena D, et al. The tolerability and efficacy of sustained dopaminergic therapy using cabergoline mono or adjunctive therapy in 202 elderly and young PD patients. A 2 year clinical observational study [abstract]. Parkinsonism Related Disord 2001; 7(S2001): S28Google Scholar
  40. 40.
    Reuter I, Flowers J, Agapito C, et al. Risk and benefit of outpatient apomorphine challenge test in parkinsonism [abstract]. Mov Disord 1998; 13Suppl. 2: 112Google Scholar
  41. 41.
    Bliwise DL, Borchert LD, Cantor C, et al. Excessive daytime sleepiness (EDS) in Parkinson’s disease (PD) patients with unintended sleep episode (USE) when treated with dopaminergic agents (DS). Parkinsonism Related Disord 2001; 7(S2001): P–TU–170Google Scholar
  42. 42.
    Chaudhuri KR. Autonomic dysfunction inmovement disorders. Curr Opin Neurol 2001; 14: 505–11PubMedCrossRefGoogle Scholar
  43. 43.
    Pal S, Lomax C, Pezzella FR, et al. The relationship of Parkinsonian nocturnal disability and excessive daytime sleepiness in Parkinson’s disease. Parkinsonism Related Disord 2001; 7(S2001): S50Google Scholar
  44. 44.
    Wetter TC, Collado-Seidel V, Pollmacher T, et al. Sleep and periodic leg movement patterns in drug-free patients with Parkinson’s disease and multiple system atrophy. Sleep 2000; 23: 363–7Google Scholar
  45. 45.
    Chaudhuri KR, Pal S, Bridgman K. Achieving 24-hour control of Parkinson’s disease symptoms: use of objective measures to improve nocturnal disability. Eur Neurol 2001; 46Suppl. 1: 3–10PubMedCrossRefGoogle Scholar
  46. 46.
    Monti JM, Hawkins M, Jantos H, et al. Biphasic effects of dopamine D-2 receptor agonists on sleep and wakefulness in the rat. Psychopharmacology (Berl) 1988; 95: 395–400CrossRefGoogle Scholar
  47. 47.
    Etminan M, Samii A, Takkouche B, et al. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease. A meta-analysis of randomised controlled trials. Drug Saf 2001; 24(1): 863–8PubMedCrossRefGoogle Scholar
  48. 48.
    Bassi S, Albizzati MG, Frattola L, et al. Dopamine receptors and sleep induction in man. J Neurol Neurosurg Psychiatry 1979; 42: 458–60PubMedCrossRefGoogle Scholar
  49. 49.
    Ulivelli M, Rossi S, Lombard C, et al. Polysomnographic characterization of pergolide-induced ‘sleep attacks’ in an idiopathic PD patient. Neurology 2002; 58: 460–1CrossRefGoogle Scholar
  50. 50.
    Barone P, Bravi D, Barmejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomised controlled study. Pergolide Monotherapy Study group. Neurology 1999; 53(3): 573–9PubMedCrossRefGoogle Scholar
  51. 51.
    Lledo A, Quail D, van Laar T, et al. An analysis of the efficacy and safety of pergolide monotherapy in the treatment of Parkinson’s disease [abstract]. Neurology 1999; 52Suppl. 2: A408Google Scholar
  52. 52.
    Olanow CW, Fahn S, Muenter M, et al. A multicenter double blind placebo controlled trial of pergolide as an adjunct to sinemet in Parkinson’s disease. Mov Disord 1994; 9: 40–7PubMedCrossRefGoogle Scholar
  53. 53.
    Shannon KM, Bennet JP, Friedman JH, et al. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 1997; 49: 724–8PubMedCrossRefGoogle Scholar
  54. 54.
    Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson’s disease. Neurology 1997; 49: 393–9PubMedCrossRefGoogle Scholar
  55. 55.
    Rascol O, Brooks D, Brunt E, et al. Ropinirole in the treatment of early Parkinson’s disease: a 6 month interim report of a 5 year L-dopa controlled study. Mov Disord 1998; 13: 39–45PubMedCrossRefGoogle Scholar
  56. 56.
    Sethi KD, O’Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson’s disease. Arch Neurol 1998; 55: 1211–6PubMedCrossRefGoogle Scholar
  57. 57.
    Brooks DJ, Abbott RJ, Lees AJ, et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson’s disease patients. Clin Neuropharmacol 1998; 21: 101–7PubMedGoogle Scholar
  58. 58.
    Lieberman A, Olanow CW, Sethi K, et al. A multicentre trial of ropinrole as adjunct treatment for Parkinson’s disease. Neurology 1998; 51: 1057–62PubMedCrossRefGoogle Scholar
  59. 59.
    Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 1996; 19: 234–45PubMedCrossRefGoogle Scholar
  60. 60.
    Rinne UK. A 5 year double blind study with cabergoline versus levodopa in the treatment of early Parkinson’s disease. Parkinsonism Related Disord 1999; 5: 84Google Scholar
  61. 61.
    Rinne UK, Bracco F, Chouza C, et al. Cabergoline delays the onset of motor complications: results of double-blind levodopa-controlled trial. Drugs 1998; 55Suppl. 1: 23–30PubMedCrossRefGoogle Scholar
  62. 62.
    Ebersbach G, Norden J, Tracik F. Sleep attacks in Parkinson’s disease: polysomnographic recordings. Mov Disord 2000; 15: 89CrossRefGoogle Scholar
  63. 63.
    British National Formulary. 42nd ed. London: British Medical Association, 2001Google Scholar
  64. 64.
    Chaudhuri KR, Pal S, Trenkwalder C, et al. Development of a novel scale for assessment of nocturnal disabilities in Parkinson’s disease [abstract]. J Neurol Neurosurg Psychiatry 2001; 70: 281Google Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • K. Ray Chaudhuri
    • 1
    • 2
    • 3
  • Suvankar Pal
    • 1
  • Christine Brefel-Courbon
    • 4
  1. 1.Guy’s King’s and St Thomas’ Medical School, King’s College LondonLondonUnited Kingdom
  2. 2.University Hospital of LewishamLondonUnited Kingdom
  3. 3.Department of Neurology, Regional Movement Disorders UnitKing’s College HospitalLondonUnited Kingdom
  4. 4.Service de Pharmacologie Clinique, University HospitalToulouseFrance

Personalised recommendations